Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical severities. New therapeutic approaches have become available in the past few years, dramatically changing the natural history of all SMA subtypes, including substantial clinical improvement with the severe and advanced SMA type 1 variant. Trials have now demonstrated that phenotypic rescue is even more dramatic when pre-symptomatic patients are treated, and emerging real-world data are demonstrating the benefits of intervention even in the chronic phase of the condition. Here, we critically review how the field is rapidly evolving in response to the new therapies and questions that the new treatments have posed, including the effects of treatment at different ages and stages of disease, new phenotypes and long-term outcomes in patients who would not have survived without treatment, and decisions of who to treat and when. We also discuss how the outcomes associated with different timing of therapeutic intervention are contributing to our understanding of the biology and pathogenesis of SMA.

Mercuri, E. M., Pera, M. C., Scoto, M., Finkel, R., Muntoni, F., Spinal muscular atrophy — insights and challenges in the treatment era, <<NATURE REVIEWS. NEUROLOGY>>, 2020; 16 (12): 706-715. [doi:10.1038/s41582-020-00413-4] [http://hdl.handle.net/10807/179615]

Spinal muscular atrophy — insights and challenges in the treatment era

Mercuri, Eugenio Maria;Pera, Maria Carmela;
2020

Abstract

Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease caused by deletion or mutation of SMN1. Four subtypes exist, characterized by different clinical severities. New therapeutic approaches have become available in the past few years, dramatically changing the natural history of all SMA subtypes, including substantial clinical improvement with the severe and advanced SMA type 1 variant. Trials have now demonstrated that phenotypic rescue is even more dramatic when pre-symptomatic patients are treated, and emerging real-world data are demonstrating the benefits of intervention even in the chronic phase of the condition. Here, we critically review how the field is rapidly evolving in response to the new therapies and questions that the new treatments have posed, including the effects of treatment at different ages and stages of disease, new phenotypes and long-term outcomes in patients who would not have survived without treatment, and decisions of who to treat and when. We also discuss how the outcomes associated with different timing of therapeutic intervention are contributing to our understanding of the biology and pathogenesis of SMA.
2020
Inglese
Mercuri, E. M., Pera, M. C., Scoto, M., Finkel, R., Muntoni, F., Spinal muscular atrophy — insights and challenges in the treatment era, <<NATURE REVIEWS. NEUROLOGY>>, 2020; 16 (12): 706-715. [doi:10.1038/s41582-020-00413-4] [http://hdl.handle.net/10807/179615]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/179615
Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 92
  • ???jsp.display-item.citation.isi??? 91
social impact